Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.79 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425456 | 1.00 | MAP2K1 (0.79) | MAP2K1CA2CA1 | |
| SCHEMBL24849675 | 0.91 | MAP2K1 (0.65) | MAP2K1CA2CA1 | |
| SCHEMBL2725937 | 0.91 | MAP2K1 (0.78) | MAP2K1CA2CA1 | |
| SCHEMBL2725911 | 0.89 | MAP2K1 (0.79) | MAP2K1CA2CA1 | |
| SCHEMBL2174993 | 0.88 | MAP2K1 (1.00) | MAP2K1CA2CA1 | |
| SCHEMBL15263205 | 0.87 | MAP2K1 (0.78) | MAP2K1CA2CA1 | |
| SCHEMBL2727076 | 0.86 | MAP2K1 (0.62) | MAP2K1CA2CA1 | |
| SCHEMBL29425515 | 0.86 | MAP2K1 (0.62) | MAP2K1CA2CA1 | |
| SCHEMBL2727914 | 0.85 | MAP2K1 (0.77) | MAP2K1CA2CA1 | |
| SCHEMBL2724893 | 0.85 | MAP2K1 (0.65) | MAP2K1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252922-A1 | SUBSTITUTED PHENOXYPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-26 | — | — | US | claimed |
| EP-4725941-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4375273-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| CN-117677607-A | Process for producing aryl amide derivative | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-31 | — | — | US | disclosed |
| EP-4186506-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-31 | — | — | EP | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| WO-2023003014-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | 中外製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-05 | — | — | US | disclosed |
| CN-114929669-A | Arylamide derivatives having antitumor activity | 中外制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021149776-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | 中外製薬株式会社 | 2021-07-29 | — | — | WO | disclosed |
| US-9045429-B2 | Substituted phenoxypyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| US-9045429-B2 | Substituted phenoxypyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20130252922-A1 | SUBSTITUTED PHENOXYPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| WO-2012055953-A1 | SUBSTITUTED PHENOXYPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | BRAF, NRAS, KRAS | MAP2K1 17/4885CA2 3972/4885CA1 4751/4885 |
| US-20130252922-A1 | SUBSTITUTED PHENOXYPYRIDINES | VEGFA, FLT1, QDPR | MAP2K1 3134/4885CA2 2022/4885CA1 4821/4885 |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, NRAS, KRAS | MAP2K1 162/4885CA2 1548/4885CA1 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.